| 158. | Maurer, M.+, Eyerich, K., Eyerich, S., Ferrer, M., Gutermuth, J., Hartmann, K., Jakob, T., Kapp, A., Kolkhir, P., Larenas-Linnemann, D., Park, H.-S., Pejler, G., Sanchez-Borges, M., Schäkel, K., Simon, D., Simon, H.-U., Weller, K., Zuberbier, T., and Metz, M.: Urticaria: Collegium Internationale Allergologicum (CIA) update 2020. Int. Arch. Allergy Immunol. 2020: 181; 321-333. IF: 2.75 |
r.158
| 291 | Hawro, T., Ohanyan, T., Schoepke, N., Metz, M., Peveling-Oberhag, A., Staubach, P., Maurer, M. and Weller, K.+: Comparison and interpretability of the available urticaria activity scores. Allergy 2018: 73; 251-255. IF: 6.77 |
| 99. | Weller, K., Zuberbier, T., and Maurer, M.: Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema. Curr. Opin. Allergy Clin. Immunol. 2015: 15; 220-226. IF: 2.77 |
r.099
| 104. | Weller, K., Peveling-Oberhag, A., Altrichter, S., Schoepke, N., Abajian, M., Zuberbier, T., Staubach, P., and Maurer, M.: Instrumente zur Erfassung von Krankheitsaktivität, Krankheitskontrolle und Lebensqualitätsbeeinträchtigung bei Patienten mit chronischer Urtikaria und Angioödemen. Allergologie 2016: 39; 6-15. IF: 0.31 |
r.104
| 128. | Bygum, A., Busse, P., Caballero, T., and Maurer, M.+: Disease severity, activity, impact, and control and how to assess them in patients with hereditary angioedema. Front. Med. 2017: 4; 212. IF: : 2.03 |
| 347 | Cherrez-Ojeda, I.+, Maurer, M., Bernstein, J. A., Vanegas, E., Felix, M., Ramon, G. D., Ensina, L. F., Larco Sousa, J. I., Matos Benavides, E. E., Cardona Villa, R., Latour Staffeld, P., Morfin-Maciel, B. M., Mori, J., Wilches, P. C.; Mata, V. L., and Cherrez, A.: Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America. World Allergy Organ. J. 2019: 12; 100011. IF: TBD (IF 2018: 3.68) |
o.347